These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33678554)

  • 1. Clostridioides difficile infection in patients with hematological malignancy: A multicenter study in Taiwan.
    Hung YP; Tsai CS; Tsai BY; Tsai PJ; Lee YT; Lee JC; Liu HC; Hsueh PR; Lee CC; Ko WC
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1101-1110. PubMed ID: 33678554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk prediction for 30-day mortality among patients with
    Chiang HY; Huang HC; Chung CW; Yeh YC; Chen YC; Tien N; Lin HS; Ho MW; Kuo CC
    Antimicrob Resist Infect Control; 2019; 8():175. PubMed ID: 31749963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
    Kurti Z; Lovasz BD; Mandel MD; Csima Z; Golovics PA; Csako BD; Mohas A; Gönczi L; Gecse KB; Kiss LS; Szathmari M; Lakatos PL
    World J Gastroenterol; 2015 Jun; 21(21):6728-35. PubMed ID: 26074711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Clostridium difficile-suspected diarrhea in a French university hospital.
    Khanafer N; Vanhems P; Barbut F; Eckert C; Perraud M; Vandenesch F; Luxemburger C; Demont C;
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2123-2130. PubMed ID: 30120646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
    Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
    Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy.
    Yoon YK; Kim MJ; Sohn JW; Kim HS; Choi YJ; Kim JS; Kim ST; Park KH; Kim SJ; Kim BS; Shin SW; Kim YH; Park Y
    Support Care Cancer; 2014 Aug; 22(8):2039-48. PubMed ID: 24595407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Inflammatory Mediators Are Effective Biomarkers for Predicting Adverse Outcomes in Clostridioides difficile Infection.
    Dieterle MG; Putler R; Perry DA; Menon A; Abernathy-Close L; Perlman NS; Penkevich A; Standke A; Keidan M; Vendrov KC; Bergin IL; Young VB; Rao K
    mBio; 2020 May; 11(3):. PubMed ID: 32371595
    [No Abstract]   [Full Text] [Related]  

  • 9. Reappraisal of the clinical role of metronidazole therapy for Clostridioides difficile infection in Taiwan: A multicenter prospective study.
    Lee JC; Lee CC; Chiu CW; Tsai PJ; Hsueh PR; Lee YT; Hung YP; Ko WC
    J Formos Med Assoc; 2022 Dec; 121(12):2608-2616. PubMed ID: 35872113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population.
    Misch EA; Safdar N
    Infect Dis Clin North Am; 2019 Jun; 33(2):447-466. PubMed ID: 31005136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance of the SHEA-IDSA severity classification for Clostridium difficile infection and the ATLAS bedside scoring system in hospitalized adult patients.
    Mulherin DW; Hutchison AM; Thomas GJ; Hansen RA; Childress DT
    Infection; 2014 Dec; 42(6):999-1005. PubMed ID: 25129565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults.
    Rao K; Micic D; Chenoweth E; Deng L; Galecki AT; Ring C; Young VB; Aronoff DM; Malani PN
    J Am Geriatr Soc; 2013 Oct; 61(10):1738-42. PubMed ID: 24083842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?
    Robin C; Héquette-Ruz R; Guery B; Boyle E; Herbaux C; Galperine T
    Med Mal Infect; 2017 Dec; 47(8):532-539. PubMed ID: 28823390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Efficacy of Therapeutic Agents for Clostridioides difficile Infection Based on Four Severity Classifications.
    Ohtani M; Yoshizawa S; Miyazaki T; Kumade E; Hirayama S; Sakamoto M; Murakami H; Maeda T; Ishii Y; Matsumoto T; Tateda K
    Jpn J Infect Dis; 2024 Sep; 77(5):281-284. PubMed ID: 38556300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy.
    Wang MS; Evans CT; Rodriguez T; Gerding DN; Johnson S
    Infect Control Hosp Epidemiol; 2013 Feb; 34(2):127-32. PubMed ID: 23295558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection.
    Falcone M; Russo A; Iraci F; Carfagna P; Goldoni P; Vullo V; Venditti M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):252-7. PubMed ID: 26482315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Observational Cohort Study of
    Rao K; Higgins PDR; Young VB
    mSphere; 2018; 3(3):. PubMed ID: 29794054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.
    Peretz A; Tkhawkho L; Pastukh N; Brodsky D; Halevi CN; Nitzan O
    BMC Infect Dis; 2016 Jun; 16():309. PubMed ID: 27334992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for complicated course and recurrence of Clostridioides Difficile infections during COVID-19 pandemic.
    Bednarska A; Sosińska-Bryła I; Hackiewicz M; Bursa D; Makowiecki M; Porowski D; Horban A
    Przegl Epidemiol; 2022; 77(1):23-33. PubMed ID: 37283245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate.
    Avni T; Babitch T; Ben-Zvi H; Hijazi R; Ayada G; Atamna A; Bishara J
    Int J Infect Dis; 2020 Jan; 90():237-242. PubMed ID: 31672656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.